G93.F Jiangsu Recbio Technology Co., Ltd.
- Market cap
- EUR 233M
- P/E
- -
- P/B
- 3.50x
- ROE
- -86.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is G93.F undervalued?
Graham numberThe Graham number of Jiangsu Recbio Technology Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Recbio Technology Co., Ltd. fundamental analysis
No fundamental analysis for Jiangsu Recbio Technology Co., Ltd. yet.
Jiangsu Recbio Technology Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical t…
Full company profileJiangsu Recbio Technology Co., Ltd. financial statements
Jiangsu Recbio Technology Co., Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 12.7M |
| Gross Profit | - | - | - | 0.00 | 11.2M |
| Operating Income | -613M | -875M | -610M | -561M | -586M |
| EBITDA | - | -692M | -495M | -462M | -479M |
| Net Income | -658M | -723M | -572M | -562M | -610M |
| EPS | -1.47 | -1.50 | -1.18 | -1.16 | -0.97 |
| Balance Sheet | |||||
| Total Assets | 1.92B | 2.31B | 2.19B | 1.94B | 1.76B |
| Total Liabilities | 246M | 657M | 1.12B | 1.41B | 1.06B |
| Shareholders' Equity | 1.67B | 1.66B | 1.07B | 529M | 706M |
| Cash & Short-term Investments | 1.18B | 1.33B | 835M | 319M | 352M |
| Cash Flow | |||||
| Operating Cash Flow | -473M | -580M | -638M | -465M | -503M |
| Capital Expenditure | 238M | 308M | 224M | 172M | 98.9M |
| Free Cash Flow | -711M | -888M | -862M | -637M | -602M |
| Ratios | |||||
| ROE | -39.3% | -43.5% | -53.4% | -106.2% | -86.5% |
| ROA | -34.3% | -31.3% | -26.2% | -29.0% | -34.6% |
| Net Profit Margin | - | - | - | - | -4,796.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jiangsu Recbio Technology Co., Ltd. dividends
Jiangsu Recbio Technology Co., Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Jiangsu Recbio Technology Co., Ltd.
- Insiders 44.89%
- Institutions 23.68%
- Public & others 31.43%
- Shares outstanding 316M
- Free float 208M
Jiangsu Recbio Technology Co., Ltd. company profile
- Company name
- Jiangsu Recbio Technology Co., Ltd.
- Ticker
- G93.F
- ISIN
- CNE1000057K9
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 466
- Fiscal year end
- December
- Address
- No. 888 Yaocheng Avenue, Taizhou, China
- Website
- recbio.cn
About Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11, which is in phase I clinical trials; REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine; and REC604c, a recombinant HPV 9-valent vaccine. It also develops REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC625, a bivalent recombinant respiratory syncytial virus vaccine and REC627, a recombinant metapneumovirus vaccine for the treatment of respiratory diseases caused by respiratory syncytial virus; REC609, a recombinant human cytomegalovirus vaccine for the treatment of human cytomegalovirus disease; and ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that completed phase III clinical trial. In addition, the company develops REC629, a recombinant Hepatitis B virus vaccine and REC630, a therapeutic recombinant Hepatitis B virus vaccine for the treatment of disease caused by hepatitis B virus infection; REC608, a recombinant herpes simplex virus vaccine; and REC617, a recombinant influenza vaccine. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.
Jiangsu Recbio Technology Co., Ltd. management
6- Dr. Yong LiuFounder, Executive Director & GM · born 1973
- Ms. Jing WangExecutive Director & Chief Quality Officer · born 1977
- Mr. Lei ZhouFinance controller · born 1986
- Dr. Kunxue HongChief Science Officer · born 1965
- Mr. Hongjun ZhouVice General Manager · born 1981
- Ms. Ka Yan SuenCompany Secretary